Virax Biolabs Group annual r&d spending
2021
2022
2023
2024
2025
2026
Virax Biolabs Group R&D Spending Growth & History (VRAX)
Virax Biolabs Group's r&d spending was $3.7M for fiscal 2026.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $3.7M | $2.0M | +110.04% |
| 2025 | 2025-03-31 | $1.8M | $217,837 | +13.95% |
| 2024 | 2024-03-31 | $1.6M | −$617,376 | −28.33% |
| 2023 | 2023-03-31 | $2.2M | $1.7M | +402.45% |
| 2022 | 2022-03-31 | $433,743 | $313,522 | +260.79% |
| 2021 | 2021-03-31 | $120,221 | — | — |
Virax Biolabs Group r&d spending trends
Over the last five fiscal years, Virax Biolabs Group's r&d spending increased from $120,221 to $3.7M, a change of $3.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group source filings ↗